ClinicalTrials.gg
CompletedNCT02470832Updated Aug 26, 2016

A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects

A Phase 1 interventional study of RG1662 and itraconazole in Healthy Patient Study, sponsored by Hoffmann-La Roche. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-26.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The study is being conducted to investigate the effect of itraconazole treatment in the pharmacokinetics of RG1662. It is also to evaluate the exposure of RG1662 vs. QTc response relationship and the safety and tolerability of RG1662 when given in combination with itraconazole in healthy subjects.

02

Conditions studied

  • Healthy Patient Study
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female volunteers
  • Ages 18 to 60 years, inclusive
  • A (BMI) between 18 to 32 kg/m2, inclusive
  • Agreement to comply with study restrictions

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy, convulsions or significant head injury or electroencephalogram (EEG) abnormalities
  • (EGC) or vital signs abnormalities
  • Significant history of drug allergy, as determined by the Investigator, or a known to any of the ingredients of any of the study treatments
  • Use of any drugs or substances that are known to be substrates, inducers or inhibitors of within 30 days of the first dose administration
  • Pregnant or lactating
  • Any other abnormalities, concomitant diseases or ongoing medical conditions
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Combination therapy RG1662 + itraconazole

    Days 20-29: Oral administration RG1662 twice daily within 30 minutes of a meal + 2 x 100 mg itraconazole once daily with food

    Drug: RG1662 · Drug: itraconazole

  • Experimental
    RG1662 Monotherapy

    Days 1-10: RG1662 120 mg twice daily (b.i.d.) within 30 minutes of a meal for 10 days (Days 1 to 9, Day 10 only a.m. dose). (Cohort A subjects will receive 1 x 120 mg RG1662 tablets twice daily. In Cohorts B and C the dose of RG1662 will be decided upon following review of the interim safety and pharmacokinetic data of the 4 subjects in Cohort A.)

    Drug: RG1662

  • Experimental
    itraconazole Monotherapy

    Days 15-19: 200 mg of itraconazole twice daily for 5 days (Days 15 to 18, Day 19 only a.m. dose)

    Drug: itraconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from 0-t (AUC0-t)

    Time frame: Within 29 days

  2. Maximum observed plasma concentration (Cmax)

    Time frame: Within 29 days

  3. Time to maximum observed plasma concentration (Tmax)

    Time frame: Within 29 days

Secondary outcomes

  1. Change from baseline in QTcF

    Time frame: Up to 29 days

  2. Incidence of adverse events

    Time frame: Within 43 days

  3. Clinically significant changes from baseline in physical examination or laboratory parameters

    Time frame: Within 29 days

  4. Mean model parameters of RG1662 concentration vs. QTcF changes

    Time frame: Within 29 days

07

Study locations

1 site
  • Leeds, LS2 9LH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2015
First posted
Jun 12, 2015
Start
May 2015
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Last update
Aug 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02470832
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 12, 2015
Start date
May 2015
Primary completion
Jul 2015
Completion
Jul 2015
Last update
Aug 26, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Basmisanil

Start the discussion